Johnson & Johnson Just Raised Its Sales Outlook Again. Here’s Why the Dividend King Is Still a Buy.
Although Johnson & Johnson‘s (NYSE: JNJ) third-quarter revenue and earnings both topped analyst estimates and the company even raised its full-year sales guidance, investors panicked over disappointing sales of medical devices. All told, the stock fell nearly 6% on Tuesday following that morning’s earnings release, adding to weakness that’s been in place since early last month.
Wise investors, however, will view this pullback from J&J shares as an opportunity rather than an omen. Although the company clearly has a couple of matters to iron out, the proverbial glass is more than half full.
Image source: Getty Images.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.